{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Agnarelli A"],"funding":["Blood Cancer UK","Leukemia UK","Wellcome Trust"],"pagination":["417-429"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9543246"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(3)"],"pubmed_abstract":["B-cell progenitor fate determinant interferon regulatory factor 4 (IRF4) exerts key roles in the pathogenesis and progression of multiple myeloma (MM), a currently incurable plasma cell malignancy. Aberrant expression of IRF4 and the establishment of a positive auto-regulatory loop with oncogene MYC, drives a MM specific gene-expression program leading to the abnormal expansion of malignant immature plasma cells. Targeting the IRF4-MYC oncogenic loop has the potential to provide a selective and effective therapy for MM. Here we evaluate the use of bromodomain inhibitors to target the IRF4-MYC axis through combined inhibition of their known epigenetic regulators, BRD4 and CBP/EP300. Although all inhibitors induced cell death, we found no synergistic effect of targeting both of these regulat"],"journal":["Hematological oncology"],"pubmed_title":["Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma."],"pmcid":["PMC9543246"],"funding_grant_id":["20003","2020/JGF/003","204833/Z/16/Z"],"pubmed_authors":["Caalim G","Mancini EJ","Agnarelli A","Milton-Harris L","Wood CD","Mitchell S","Chevassut T","West MJ"],"additional_accession":[]},"is_claimable":false,"name":"Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.","description":"B-cell progenitor fate determinant interferon regulatory factor 4 (IRF4) exerts key roles in the pathogenesis and progression of multiple myeloma (MM), a currently incurable plasma cell malignancy. Aberrant expression of IRF4 and the establishment of a positive auto-regulatory loop with oncogene MYC, drives a MM specific gene-expression program leading to the abnormal expansion of malignant immature plasma cells. Targeting the IRF4-MYC oncogenic loop has the potential to provide a selective and effective therapy for MM. Here we evaluate the use of bromodomain inhibitors to target the IRF4-MYC axis through combined inhibition of their known epigenetic regulators, BRD4 and CBP/EP300. Although all inhibitors induced cell death, we found no synergistic effect of targeting both of these regulat","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-22T12:07:34.372Z","creation":"2025-04-06T00:12:07.172Z"},"accession":"S-EPMC9543246","cross_references":{"pubmed":["35544413"],"doi":["10.1002/hon.3016"]}}